Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZR2 vs R-CHOP in elderly newly diagnosed DLBCL
NCT05428670Phase 2Unknown
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Jun 2022
- Primary completion
- May 2025
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of zanubrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Status: unknown.
02
Drugs
zanubrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05428670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05428670.